Anthem Biosciences Q1 FY26 earnings call
In brief
Anthem posted Q1 FY26 revenue of ₹540 cr, EBITDA of ₹214.3 cr (38% margin) and ₹785 cr net cash; reiterated ~20% growth guidance.
- Management's tone
- Confident
- What was said
- Leaned positive
- Guidance
- Guidance held
- Analyst pushback
- Medium
- Stock, next session
- +9.27% (Nifty 50 +0.05%)
- Q1 FY26 consolidated revenue ₹540 cr with EBITDA ₹214.3 cr at 38% margin; CRDMO ₹452.7 cr, specialty ingredients ₹87.5 cr.
- Net cash position ₹784.8 cr as of June 30, 2025, with ~₹150 cr capex commitment for units 2 and 3.
- Two Phase 3 molecules approved in Q1; commercial portfolio rose from 10 to 12, Phase 3 reduced from 10 to 8.
- Added 54 KL of custom synthesis capacity at Unit 2 in Q1 FY26; balance 76 KL and 25 KL NeoAnthem peptide capacity targeted in calendar 2025.
- CEO called Q1 'exceptional' from commercial product uptake across 5-6 clients; reiterated ~20% YoY growth for FY26.
An AI read of the company's transcript · the filing
The numbers
The quarter, Q1 FY26
| This quarter | A year ago | Last quarter | Margin | |
|---|---|---|---|---|
| Revenue | ₹540 cr | — | — | |
| EBITDA (excl. other income) | ₹191 cr | — | — | 35.4% |
| Net profit | ₹0 cr | — | — | 0% |
| EPS (₹) | ₹2.43 | — | — |
From the company's filed results for the quarter ended 30 Jun 2025 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.
Where management's figures differ from the filing
- EBITDA: said ₹214.3 cr with EBITDA margins at 38%; filed ₹191.49 cr (margin 35.4%). Management's ₹214.3 cr appears to include other income of ₹22.81 cr; filed EBITDA is computed excluding other income.
What moved the numbers, as management explained it
- Commercial product demand from 5-6 clients lifted revenue; CEO called Q1 'exceptional' due to lumpy nature of commercial sales.
- ESOP/share-based compensation charge of ₹4.4 cr in Q1 FY26 (not in Q1 FY25) impacted margins by ~0.8 pp; should not extrapolate. (one-off)
- Q4 FY25 had higher R&D revenue share at ~16% of CRDMO versus ~11% in Q1 FY26, which lifted Q4 material margin in comparison.
- Other expenses up sharply on commissioning of 54 KL Unit 2 (power, fuel) and higher CSR in Q1; CSR will tone down over full year.
- Backward integration for a key intermediate completed; benefits to flow through gross margins in coming quarters.
The numbers management led with
- Net cash position: INR 784.8 crores as of June 30, 2025 (~INR 750 cr cash)
- Custom synthesis capacity addition: 155 KL total (130 KL Unit 2 + 25 KL NeoAnthem); 54 KL commissioned in Q1 FY26; balance 134 KL in CY2025
- Commercial molecule portfolio: Expanded from 10 to 12 in Q1 FY26 after 2 Phase 3 approvals
- Unit 2 + 3 capex commitment: ~INR 150 crores remaining commitment
Guidance
Guidance on this call
| What | For | What management said | Filed |
|---|---|---|---|
| Consolidated revenue growth | FY26 | Outlook more or less the same: ~20% growth YoY for FY26 vs FY25 and going forward. | — |
| Full-year growth in line with 10-year historical | FY26 | We will still maintain that for the year. Our growth should be in the range of our historical -- 10-year historical growth, which is about 22%. | — |
| EBITDA margin | FY26 | Directionally ~38% on an overall number for an FY '25 basis; we'll continue in the same zip code for both EBITDA and gross margin. | 38.1%, within the range |
Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.
The business
By business
CRDMO
Q1 FY26 revenue ₹452.7 cr; R&D ~₹50 cr and D&M ~₹400 cr; commercial portfolio rose to 12 after two Phase 3 approvals; Europe 55-60% of CRDMO.
Revenue ₹452.7 cr · R&D revenue ~₹50 cr · Development & manufacturing ~₹400 cr · Europe 55-60% of CRDMO · Commercial portfolio 12 (up from 10) · Phase 3 8 (down from 10)
Outlook: CEO reiterated ~20% YoY growth; commercial growth mirrors end-molecule sales; CRO remains ~10% of revenues.
Specialty Ingredients
Q1 FY26 revenue ₹87.5 cr; 15% of revenues from domestic; backward integration complete; benefits on gross margins expected in coming quarters; GLP-1 participation active.
Revenue ₹87.5 cr · Domestic 15% of revenues
Outlook: Gross margin benefit from backward integration to flow in coming quarters; GLP-1 participation with multiple customers ongoing.
Balance sheet, capex and funding
- Net cash position ₹784.8 cr as of June 30, 2025 (close to ~₹750 cr cash).
- Capex commitment for Unit 2 and Unit 3 expansion ~₹150 cr; funded largely from treasury.
- Unit 4 greenfield expansion just had groundbreaking; multi-year project, capex details to be firmed up in coming months.
- Open to borrowing at attractive rates if needed; will stay net cash positive.
The industry, as management sees it
Management views the CDMO industry as currently operating in a politically uncertain environment (US tariff noise, MFN pricing rhetoric), but believes Anthem has navigated past cycles (2008, COVID) and that current customer pricing discussions remain normal. Peptide/GLP-1 opportunity post-patent expiry is flagged as a structural growth driver; new modality uptake (ADC, RNA) still in early stage with longer gestation. Customer-side pricing pressure not seen today but flagged as a watch item.
Risks management named
- Lumpiness of commercial molecule revenues — Q1 was an exceptional quarter
- Geopolitical and tariff/MFN pricing uncertainty on US-bound products
- Long gestation for new modalities to translate into material revenue
- Capacity build is ahead of customer awards — execution risk if approvals slip
Q&A
Q&A was dominated by three themes: (1) capacity expansion granularity and funding strategy, with management giving clear visibility on the 134 KL custom synthesis and 40 KL fermentation additions and reiterating INR785 cr net cash as primary funding; (2) growth sustainability — management flagged Q1 as 'exceptional/lumpy' and reiterated the ~20% historical CAGR as the FY26 anchor rather than upgrading; (3) product/client specifics on the 2 newly commercialized molecules, where management declined to disclose therapeutic area, client identity, or revenue contribution citing CDAs. Pushback was mild to moderate — Nomura's host analyst Saion Mukherjee pressed on tariff pass-through and US facility logic; JP Morgan pushed on commercial wallet share upside; JM Financial pushed on lateral projects and BD footprint. Management handled most questions with specifics except where bound by CDAs.
Not answered directly
- Therapeutic area and client identity of newly commercialized molecules
- Revenue share contribution of new commercial products
- End-market traction of newly commercial molecules
- Timeline for early-stage ADC projects moving to late stage
- Gross margin split between CRO and CMO within CRDMO
Asked for a number, answered without one
- Unit 4 capex and timeline: Unit 2 and 3 capex commitment close to ~₹150 cr to be completed; Unit 4 in very early planning stage; will come back with firm plans and capex numbers in coming months.
- Therapeutic area and client details of newly approved molecules: Signed CDAs with respect to particular products or clients; not supposed to disclose anything about the product or client; only said these are established pharma companies.
- Share of new molecules in overall sales: Will not disclose those numbers; bound by agreements.
- Gross profit margin split between CRO and CMO: Will not give gross profit margin split; only gave R&D (~₹50 cr) vs development and manufacturing (~₹400 cr) revenue split.
Every question, with its answer
1. Capacity expansion roadmap
Ankush Mahajan, Centrum Wealth
Question. On capacity — custom synthesis is 270 KL with 1,155 KL planned; what is the phasing of incremental capacity in coming quarters? Fermentation is 142 KL — how much incremental will be added?
Answer, Management, Anthem Biosciences management. Custom synthesis expansion: 54 KL commissioned in Q1 FY26 at Unit 2; balance 76 KL in Unit 2 and 25 KL at NeoAnthem to complete by this calendar year. Fermentation: 40 KL being added at NeoAnthem, also in this calendar year. Unit 4 groundbreaking done in Q1; details to be firmed up over next couple of months. Capacity utilization ~70% custom synthesis, ~50% fermentation; peptide capacity (~16 KL) sits within NeoAnthem custom synthesis expansion.
Follow-up. Capacity utilization in custom synthesis and fermentation last quarter? Does peptide sit under fermentation?
Answer. Custom synthesis utilization similar to prior year at ~70%; fermentation ~50%. Peptides are part of custom synthesis — 16 KL within the 25 KL NeoAnthem expansion.
2. Quarterly growth drivers
Vivek Agrawal, Citigroup
Question. Y-o-Y growth strong but on a low base; Q-o-Q growth is ~15% even though customers typically stock inventory into March. What helped you buck the trend — wallet share on existing products or new product ramp?
Answer, Ajay Bhardwaj, Managing Director & CEO. Q1 bump was driven by commercial products broadly — not one product but several with global partners. Management explicitly called it an 'exceptional quarter' and warned that business is lumpy; would not extrapolate to every quarter.
Follow-up. Any change in full-year outlook vs prior? And on Q-o-Q gross margin dip — is it mix or other?
Answer. Outlook: maintain ~20% CAGR growth FY26 vs FY25; prefer to wait through Q2–Q4 before firming. Margins have been steady YoY; Q-o-Q margin dip reflects lower R&D revenue share in Q1 (~11%) vs Q4 FY25 (~16%), raising material margin in Q4. Also Q1 has INR4.4 cr ESOP charge absent in Q1 FY25 (~0.8% margin impact).
3. Pricing environment, backward integration, pipeline
Bansi Desai, J.P. Morgan
Question. Broader question on pricing environment given MFN policy and political rhetoric on drug pricing — what is the CDMO pricing pressure picture? And on backward integration of a key molecule — where does it stand? And update on late Phase 3 pipeline (10 odd molecules from RHP).
Answer, Ajay Bhardwaj, Managing Director & CEO. Pricing: no undue pressure from customers; Anthem has navigated 2008 and COVID and will adapt if adverse policies emerge. Backward integration: complete; no longer reliant on external source for the key intermediate — gross margin benefit to flow in coming quarters. Late pipeline: 2 of the 10 Phase 3 molecules got approved and moved to commercial; commercial portfolio now 12 (was 10), Phase 3 down to 8. Success of newly commercial products in end markets yet to be seen.
4. Monoclonal antibody capacity
Devanjan Bhakta, Universal General Insurance
Question. Do we have capacity in monoclonal antibodies (bioreactors) or will that be fulfilled by fermentation capacity?
Answer, Ajay Bhardwaj, Managing Director & CEO. Currently only lab-scale mAb research for clients; no commercial mAb setup yet. Driven by client needs — as projects move to commercialization, Anthem will add antibody production capacity. Working on cell-based manufacturing for several projects; not yet commercial.
5. New modalities and lateral projects
Amey, JM Financial
Question. Color on new modalities (ADC, RNA, etc.) — when can they start contributing commercially? And on lateral vs own product pipeline — are we looking at lateral projects given dependence on own pipeline today?
Answer, Management, Anthem Biosciences management. Modalities: scaled from lab to commercial — ADC commercial facility commissioned at Hypotent, peptides commercial-scale commissioned, RNA/lipids at commercial/development-batch level. Several products still in development; status quo on numbers since March 25. Lateral projects: 'very much on the cards'; one project already ramping; conversations with customers on becoming second source ongoing.
6. Capex, funding and growth driver mix
Harpreet Kaur, Samar Wealth Advisors
Question. What is the expected capex for Unit 3 and Unit 4 in coming years? Internal accruals or borrowings? And this quarter 60% revenue growth — was it volume-driven or value-driven?
Answer, Management, Anthem Biosciences management. Capex: ~INR150 cr for Unit 2 + 3 completion. Unit 4 still in planning; numbers to be shared once firmed. Funded mainly from INR785 cr net cash; open to borrowings at attractive rates but intent to stay net-cash positive. Growth driver: 5–6 clients across product categories with larger volumes required. Historical 10-year growth is ~22%; FY26 should be in that range — Q1 exceptional, not every quarter.
7. Capacity strategy and competitive positioning
Sajal Kapoor, Antifragile Thinking
Question. Would you wait for innovator contracts before adding capacity or build ahead? Where is the line between caution and missed opportunity? And what are Anthem's top weaknesses today?
Answer, Ajay Bhardwaj, Managing Director & CEO. Capacity built ahead of curve — anticipates client needs. Operating at 70% utilization and still adding. Has not missed opportunities due to capacity in the past; does not expect that in the future. Weaknesses: hardest to identify; biggest uncertainty is geopolitical. Strengths: interdisciplinary chemistry-biology, continuous + batch manufacturing, automation — will keep pushing the technology agenda.
8. Geography, CRDMO mix and modality economics
Tushar Manudhane, Motilal Oswal Financial Services
Question. Geographic revenue split US/Europe and constant currency growth? And within CRDMO, split of CRO vs CMO with respective gross margins? Also profitability/return ratios on ADCs and peptides — timeline and contour?
Answer, Gawir Baig, Chief Financial Officer. Mix: 15% domestic (largely specialty ingredients); CRDMO ~55–60% Europe, ~40% US. FX gain ~INR3 cr in other income this quarter. CRDMO split: R&D ~INR50 cr, development + manufacturing ~INR400 cr; margin split not disclosed. New modalities still in development — small volumes, longer gestation; margin profile similar to existing business in development batches.
Follow-up. What gives Anthem the right to win in these new modality segments where established players already exist?
Answer. Anthem has been engaged with customers from early development — by commercialization, has worked on molecule for 7–8+ years and knows it more than anyone else. Already working across multiple projects and modalities with customers.
9. Margin outlook and other expenses
Amlan Jyoti Das, Nomura
Question. EBITDA and gross margin outlook for this year and coming couple of years? And Q1 FY26 other expenses jumped ~90% YoY — any one-off?
Answer, Management, Anthem Biosciences management. Margins: looking at steady EBITDA, gross and PAT margins — close to ~38% zip code in FY25 expected to continue. Other expenses: up due to NeoAnthem + Unit 2 commissioning (power, fuel) and higher CSR in Q1 (which will tone down over the year).
10. Newly commercialized molecules disclosure
Jash Gandhi, Dalal & Broacha
Question. On the 2 newly commercialized molecules — which therapeutic areas and biotech vs big pharma? Are they part of Q1 numbers? Traction in end market?
Answer, Management, Anthem Biosciences management. Therapeutic area/client specifics: cannot disclose due to CDAs. Customer type: established pharma companies. Q1 contribution: marginal — early days. End-market traction: too early to comment. Will not disclose specific revenue share of new products due to client agreements.
Follow-up. Traction on existing commercial molecules (blockbusters historically)? And are new molecules ~5–7% of overall sales?
Answer. Cannot comment on client/product specifics. New molecule revenue share will not be disclosed due to binding agreements.
Not answered directly.
11. Tariffs, US facility and M&A
Saion Mukherjee, Nomura
Question. Discussion with customers on pricing given tariff noise — is a US facility being considered? If tariff imposed tomorrow, can Anthem pass on day 1 impact? And given fast technology change, build capabilities organically or look at acquisitions?
Answer, Ajay Bhardwaj, Managing Director & CEO. Tariff: most sales go to Europe where product is formulated before US shipment — direct tariff exposure limited; some products still classified as chemicals not drugs. US facility: 7–8 year cycle, expensive; acquisition path possible but commercially tough — open if right target. Tech capabilities: mostly build from ground up; M&A for newer modalities is hard since no historical players exist; would consider acquisition if a target exists for established modalities. Also split by customer type: CRDMO is pure-play innovative — no generic work.
Follow-up. Customer/product concentration in INR450 cr CRDMO — big pharma vs emerging pharma split?
Answer. Mix largely in line with March 25. Commercial portfolio is largely from big companies; development portfolio comes from emerging biotech. Percentages broadly the same with marginal one or two percentage variation.
12. Commercial portfolio growth and GLP-1 opportunity
Bansi Desai, J.P. Morgan
Question. Growth outlook for commercial portfolio — will it track end molecule sales or can wallet share increase / forward integrate? And with GLP-1 going off patent, will peptide capacity drive specialty ingredients growth? Can Anthem compete with Chinese suppliers?
Answer, Gawir Baig, Chief Financial Officer. Commercial portfolio growth: deepening customer engagement; weekly discussions on additional projects. Will not commit to wallet share expansion — intent is to keep wallet share intact and mirror customer growth. GLP-1: Anthem is a serious player; actively in conversation with multiple pharma companies; believes it will be a leading producer; can compete with Chinese suppliers.
Partly answered.
13. BD strategy and CRO focus
Amey, JM Financial
Question. Plans to put BD teams in geographies like Europe vs continuing from India? And CRO business — plans to develop it further? FFS vs FTE mix going forward?
Answer, Ajay Bhardwaj, Managing Director & CEO. BD: US BD very well established via partners for 19 years; no compelling reason to add own BD on ground — costs would escalate significantly. CRO ~10% of revenue; integral as feeder for development/commercial pipeline; FFS to remain dominant mix, but open to FTE if client proposes. Will continue adding scientific staff and lab capacity (some in Unit 2/3 capex).
14. Customer mix by type
Devanjan Bhakta, Universal Sompo General Insurance
Question. Revenue split by originator vs generic customers?
Answer, Management, Anthem Biosciences management. CRDM business is pure-play innovative focused — no generic work.
15. ADC capabilities and pipeline stage
Amlan Jyoti Das, Nomura
Question. ADC capabilities — do we have conjugation capability? Stage of latest ADC project? Of 5–6 early-stage ADC projects, will any move to late stage early this year?
Answer, Management, Anthem Biosciences management. ADC: have done conjugation of warhead with linker and with mAb; full capability across multiple projects; no commercial ADC project yet. Latest ADC still in late stage; status quo. Timeline for early stage to late stage refrained from comment — discovery timelines hard to predict.
Partly answered.
What was said
Topic by topic, in the order it was spoken
Opening Remarks — Q1 FY26 Headline Numbers · Ajay Bhardwaj (MD & CEO)
- Strong YoY growth in Q1 FY26 reflecting CRDMO revenue stream that started ramping up from Q2 FY25.
- Consolidated revenue INR540 cr: CRDMO INR452.7 cr, Speciality Ingredients INR87.5 cr.
- EBITDA INR214.3 cr at 38% margin; PAT INR135.8 million (24% margin) — first call after listing.
- Net cash INR784.8 cr (~INR750 cr cash) — funds future expansion.
Capacity Expansion Roadmap — Units 2, 3, 4 and NeoAnthem · Management
- Custom synthesis: 54 KL commissioned in Q1 FY26 at Unit 2; balance 76 KL in Unit 2 plus 25 KL in NeoAnthem to complete this calendar year — full 134 KL expansion this year.
- Fermentation: 142 KL base, adding 40 KL at NeoAnthem, also targeted for this calendar year — completes Unit 2 and 3 expansion.
- Unit 4 greenfield: groundbreaking done in Q1 FY26; capacity numbers to be firmed up over next couple of months.
- Current utilization: ~70% custom synthesis, ~50% fermentation — capacity addition is anticipatory, ahead of customer awards.
Commercial Molecule Performance and Pipeline Movement · Ajay Bhardwaj (MD & CEO)
- Q1 growth driven by larger volumes from 5–6 commercialized clients/molecules — broadly spread, not one product.
- Commercial portfolio rose from 10 to 12 after 2 approvals from Phase 3; Phase 3 pipeline reduced from 10 to 8.
- Management emphasized Q1 was 'exceptional' and lumpy — expects to deliver ~22% historical growth for the year.
- Newly commercial molecules are marginal contributors in Q1; launch traction still early.
New Modalities — ADCs, Peptides, RNA/Lipids, mAbs · Management
- ADC: commercial-scale facility commissioned at Hypotent; full conjugation capability including warhead, linker and mAb conjugation demonstrated to customers; no commercial project yet.
- Peptides: commercial-scale facility commissioned; 16 KL of peptide capacity within the 25 KL NeoAnthem expansion.
- RNA/lipids: at commercial/development-batch level; moving from lab scale upward.
- Monoclonal antibodies: only research-scale at present; commercial capacity to be added once client projects commercialize.
Margins, Mix and Backward Integration · Management
- Q1 PAT includes INR4.4 cr share-based compensation charge not present in Q1 FY25 — adjusted EBITDA margin ~38% YoY.
- Q4 FY25 had higher material margin because R&D revenue was ~16% of CRDMO vs 11% in Q1 — mix-driven, not underlying deterioration.
- Backward integration of a key intermediate complete — gross margin benefit to accrue from coming quarters.
- EBITDA, gross and PAT margins guided steady in the ~38% zip code; other expenses up on Unit 2 commissioning (power/fuel) and higher CSR.
Tariff, MFN Pricing and US Facility Considerations · Ajay Bhardwaj (MD & CEO)
- No unusual pricing pressure from innovator customers currently; normal volume-vs-price discussions only.
- Most CRDMO volume goes to Europe (~55–60%) where customers formulate before US shipment, limiting direct US tariff exposure.
- Setting up a US facility described as a 7–8 year cycle and commercially unattractive; open to inorganic acquisition if a compelling target arises.
Geography, Revenue Mix and Customer Concentration · Gawir Baig (CFO)
- 15% of revenue from domestic (specialty ingredients); within CRDMO ~55–60% Europe, ~40% US.
- CRDMO split: R&D ~INR50 cr, development + manufacturing ~INR400 cr; percentages broadly unchanged vs FY25.
- Commercial portfolio largely tied to big pharma; development portfolio feeds from emerging biotech — same shape as FY25.
- FX gain of ~INR3 cr recognised in other income this quarter.
Growth Drivers and Growth Outlook · Ajay Bhardwaj (MD & CEO)
- Reiterated ~20% YoY growth outlook for FY26 vs FY25; would prefer to wait through Q2–Q4 before upgrading.
- GLP-1 peptide opportunity: Anthem 'will be a serious player' and 'leading producer'; competitive against Chinese suppliers.
- 10-year historical growth rate cited at ~22% — used as the FY26 anchor.
Capex, Funding and Treasury · Management
- Unit 2 + 3 capex commitment ~INR150 cr to be completed this year.
- Unit 4 is a multi-year greenfield — exact capex to be communicated once firmed up.
- Funded primarily from ~INR785 cr net cash; willing to borrow at attractive rates but intent to stay net-cash positive.
- Specialty ingredients business helps fill capacity during client approval wait.
BD Strategy, Lateral Projects and CRO · Ajay Bhardwaj (MD & CEO)
- No plans to set up own BD offices in US/Europe; current model with partners has worked for 19 years.
- Lateral/second-source projects 'very much on the cards' — one project already ramping; more discussions ongoing.
- CRO (R&D) ~10% of revenue but treated as the feeder for development and commercial pipeline; FFS-heavy mix to continue.
- R&D scientist hiring and lab capacity (in Unit 2/3 capex) explicitly flagged as growth driver for CRO/FFS.
Strategic Philosophy and Closing · Ajay Bhardwaj (MD & CEO)
- Capacity always built ahead of curve — 'never found wanting in capacity' is the model.
- Strengths: interdisciplinary chemistry-biology, continuous + batch manufacturing, automation; weakness acknowledged as geopolitical uncertainty.
- Closing remarks: first earnings call, thanks participants, looks forward to ongoing engagement.
In their words
The whole basis of this model, which was an innovative model that we designed is this, that while our projects move along the pipeline towards commercialization, these are our clients' projects. As we get approvals, which also take time, we will be able to use our capacities to fill in with our own products.
Anthem will be a player, a serious player in GLP-1. Because it is a, this is, it is not a me-too type of product. And we believe that our competitive strengths will allow us to be one of the, I would say, the leading producers of GLP-1. Surely.
Anthem has a front row seat in drug development. And I say that very emphatically. We know what the thinking of drug developers is and what do they need and anticipating their need is Anthem's forte and we'll keep doing that.
To check next time
What management committed to on this call, or the dates they gave.
- Q2 FY26 performance to confirm whether Q1's 60% YoY growth was truly 'exceptional' or sustainable.
- Completion of 76 KL custom synthesis capacity (Unit 2) targeted within calendar 2025.
- 25 KL NeoAnthem peptide synthesis capacity commissioning targeted in H1 FY26.
- 40 KL NeoAnthem fermentation capacity commissioning targeted in calendar 2025.
- Gross margin benefits from completed backward integration expected to flow in.
- Unit 4 capex details and expansion plans to be firmed up over coming months.
Transcript
We have not transcribed this call's recording. Read the company's transcript (PDF).
The stock after the call
| After the call | Close | Stock | Nifty 50 |
|---|---|---|---|
| Next session Thu 14 Aug 2025 | ₹824.95 | +9.27% | +0.05% |
| 5 sessions Thu 21 Aug 2025 | ₹846.35 | +12.11% | +1.89% |
| 20 sessions Fri 12 Sept 2025 | ₹833.50 | +10.40% | +2.01% |
From the close of Wed 13 Aug 2025, ₹754.95: the close before the call day (the call's time is not on file). Adjusted daily closes; the move includes everything else that happened in those sessions.